lance; this issue is likely to remain debated until the significance of occult regional metastases is better understood.
Level VI is the first echelon of lymphatic metastasis and is the level the most frequently involved by PTC. 1 However, the question is not only to predict if this level is involved, but also to determine if routinely treating it will improve disease control in the context of routine radioactive iodine ablation. Beyond this, does the surgical morbidity of dissecting level VI in all patients with PTC outweigh the morbidity of recurrent disease in a few? Furthermore, do all recurrences require treatment or can selected patients be observed? These fundamental questions have sparked considerable discussion on the utility of systematic paratracheal dissection for PTC. [2] [3] [4] Traditionally in our institution, elective lateral or central compartment neck dissections are not routinely performed. A neck dissection will be undertaken if there are clinical or radiological enlarged or biopsy-proven positive lymph nodes at the time of diagnosis, or if suspicious nodes are identified intraoperatively at the time of the thyroidectomy. More recently, however, some surgeons have followed the trend toward an ipsilateral elective paratracheal dissection.
The aim of this study was to review patients treated for PTC in our institution and to report the rate and pattern of locoregional recurrence in patients treated with and without central compartment dissection. Furthermore, this work intends to identify prognostic factors influencing locoregional control and disease specific survival in our cohort.
METHODS
The study cohort comprises 342 of 406 patients with papillary thyroid carcinoma who have been treated at the Sydney Head and Neck Cancer Institute, Royal Prince Alfred Hospital, Australia, between 1982 and 2007. Since 1987, clinicopathologic data of patients treated at the Sydney Head and Neck Cancer Institute have been prospectively recorded on a computerized database. All patients included underwent total thyroidectomy for papillary thyroid carcinoma regardless of whether a neck dissection was performed as part of their primary treatment. To be included in the study, follow-up information and histopathology reports had to be available and complete. Patients who underwent hemithyroidectomy with a coincidental micropapillary carcinoma were excluded.
The maximum diameter of the largest focus of papillary carcinoma was collected. Micropapillary carcinoma was defined as tumor less than 10 mm. Tumor grade and differentiation, thyroid capsule invasion and extrathyroidal extension, lymphovascular invasion, T stage (based on the 6th edition of the AJCC TNM staging system) were among the histopathologic features recorded.
The type of neck dissection performed was specifically reviewed and collated. Patients were classified as having a lateral neck dissection, which includes levels II to V (no patient had a level I dissection) and/or a central compartment neck dissection, which includes levels VI to VII. Central compartment dissection represents a heterogeneous group of patients undergoing either ipsilateral or bilateral level VI +/− VII dissection depending on the indication for dissection. When an elective central dissection was performed this was usually restricted to an ipsilateral level VI dissection. When a therapeutic dissection was performed, this usually included bilateral level VI and VII. Patients with a positive lymph node biopsy or coincidental nodes identified on histopathology were included in the "node positive" group but not coded as undergoing neck dissection.
Radioactive I-131 ablation (RAI) was given to patients with macropapillary or multifocal thyroid carcinoma when possible. Patients with micropapillary carcinoma received radioactive I-131 when there were positive lymph nodes on pathology and/or tumor extension beyond thyroid capsule and/or multifocal thyroid carcinoma.
Patients received sufficient doses of thyroxin to suppress thyrotropin (TSH) levels according to risk and had routine periodic (at least annual) clinical examination, whole body scans (I-131 or I-123) and serum thyroglobulin and antithyroglobulin levels. The frequency of thyroxin withdrawal has decreased overtime and more recently r-TSH stimulated whole body scans, thyroglobulin and positive emission tomography scans have been incorporated.
Locoregional recurrence was defined as either pathological evidence of disease on excision or cytology, or where 2 surveillance modalities confirmed recurrent disease (eg, elevated thyroglobulin and whole-body scan). When possible, locoregional recurrence was managed with surgical excision and repeat radioactive iodine therapy. Overall, 6 patients with elevated serum thyroglobulin levels were not treated surgically for persistent/recurrent thyroid cancer.
Locoregional control and disease specific survival were calculated using Kaplan-Meier method and single variables were compared using the logrank test. Multivariable analysis was carried out using the Cox proportional hazards model. Data was collated and filtered using Excel (Microsoft, USA) and the statistical analysis was performed using SPSS version 12.0 (SPSS Inc, Chicago, Ill).
RESULTS
Of 342 patients included in this study, there were 257 women and 85 men with a median age at diagnosis of 45 years (range, 13-94). Median follow-up was 34 months (range, 7 months to 22 years). The mean follow-up was 4.3 years. Clinical and pathologic information is summarized in Table 1 .
All patients underwent total thyroidectomy, of which 76 underwent a completion thyroidectomy after an initial diagnostic hemithyroidectomy. Eighty-four patients underwent neck dissection as part of their primary treatment. Thirty-four patients had both lateral and central compartment neck dissection, 18 patients had a lateral neck dissection alone and 32 patients had only a central compartment dissection (Table 2 ). In total, 66 patients underwent a central compartment neck dissection.
The median diameter of PTC was 18 mm. Eighty-three patients had a micropapillary carcinoma, 212 patients had tumors between 10 and 40 mm, and 47 had tumors greater than 40 mm.
Radioactive Iodine Treatment
Radioactive iodine data were retrieved for 331 of 342 patients. On the basis of the data available, the mean cumulative dose of radioactive I-131 was 153 mCI and the median cumulative dose was 105 mCI (range, 5-1189). Seventy patients did not receive RAI ablation treatment. Among them, 60 had micropapillary carcinoma (median size, 5 mm; range, 0.2-37 mm). Two of the patients who did not receive RAI ablation treatment underwent a central neck dissection at the time of the total thyroidectomy. One had an elective bilateral central neck dissection done with no positive lymph nodes on histopathology analysis. The second patient had an ipsilateral level VI neck dissection that showed 1 positive lymph node. None of these 70 patients developed locoregional recurrence on follow-up.
Overall, 64 of 66 patients who underwent a central neck dissection received RAI ablation and 18 patients (28%) required multiple RAI ablations. In comparison, 267 of 278 patients who did not undergo central neck dissection received RAI ablation and 29 patients required multiple RAI ablations (11%). There is a significantly higher rate of multiple RAI ablation treatments (compared to no or single RAI) in the central neck dissection group (P = 0.0023). Because in our study a central neck dissection was mainly performed as a therapeutic dissection, this finding is likely to reflect more aggressive disease in patients undergoing central compartment dissection.
Distant Control and Survival
Ten patients had distant metastases at the time of diagnosis. Four patients died from metastatic papillary thyroid carcinoma and 3 patients died from other malignancies or unrelated causes.
In this unselected cohort, the cumulative overall survival was 95% and 89% at 10 and 20 years, respectively (Figure 1 ). The cumulative disease specific survival was 96% at both 10 and 20 years ( Figure 2 ). Although the cumulative disease specific survival rates at 10 years were 99% for women and 91% for men, these results were not statistically different (P = 0.83). surgery (1 received adjuvant external beam radiotherapy) and 1 patient was treated with radioactive iodine ablation treatment alone. Two patients had local and regional recurrences: 1 was treated with RAI alone and the other patient underwent a level II to V neck dissection with tracheal resection for tracheal invasion by the cancer. Twentythree patients (6.7%) developed regional recurrence. Twelve did not have a neck dissection as part of the initial surgery. Of the remaining 11 patients who underwent an initial neck dissection, levels dissected are as follow: ipsilateral VI (n = 3), ipsilateral II to IV (n = 3), ipsilateral II to IV + bilateral VI to VII (n = 1), ipsilateral II to V + VI (n = 1), ipsilateral II to IV + VI (n = 1), ipsilateral II to V (n = 1) and ipsilateral V + VI (n = 1).
The majority of neck recurrences were found in the lateral neck (n = 19), predominantly in levels 4 and 3, rather than in the central neck (n = 8) even when no central compartment dissection was performed. The nodal distribution of regional recurrences according to neck dissection is reported in Table 3 .
We have extrapolated the potential effect of prophylactic central compartment neck dissection in this cohort. Two hundred seventysix patients did not undergo any form of central neck dissection. Of those, 6 patients (2.2%) recurred in the central neck compartment. Among them, 4 had concurrent disease in the lateral neck of which one had bilateral disease (Table 3) . Hence, only 1 patient (0.4%) may have been spared further surgery if a prophylactic bilateral level VI and VII dissection was performed and another patient (0.4%) may have avoided additional surgery if an ipsilateral central dissection was done electively initially.
Single Variable Analysis
Pathological variables found to be significant predictors of improved locoregional control included micropapillary carcinoma (P = 0.05), tumor size less than 40 mm (P = 0.001), absence of extrathyroidal extension (ETE) (P = 0.001) or lymphovascular invasion (P = 0.004), and node negativity (P = 0.03). In comparison, only ETE (P = 0.01) was a significant adverse prognostic variable for disease specific survival. Tumor size (P = 0.43), T-stage (P = 0.16), and positive lymph nodes (P = 0.85) were not significant.
Neck dissection (central compartment or lateral) did not improve locoregional control or survival; however, most patients underwent a therapeutic neck dissection.
Looking specifically at the central neck compartment control rate, we found that patients without ETE or lymphovascular invasion had better control (P = 0.01 and P = 0.007, respectively) and tumors less than 40 mm demonstrated a trend toward better control (P = 0.09). Neither nodal status nor having had a central neck compartment dissection was associated with improved central neck compartment control.
Multiple Variable Analysis
Because most patients who underwent neck dissection had a therapeutic dissection, a regression analysis was performed to see if there was any evidence for improved locoregional control or survival in patients undergoing central compartment dissection when adjusting for adverse pathological features that predicted for locoregional failure. When adjusted for size of tumor, ETE, lymphovascular invasion and positive nodes, paratracheal dissection was not found to be a predictor of locoregional control nor central neck compartment control (Figures 4 and 5) . Extrathyroidal extension (HR 0.29; P = 0.006) and lymphovascular invasion (HR = 0.8; P = 0.04) were the only significant independent predictors of locoregional recurrence. radioactive iodine ablation or a prophylactic neck dissection. Although therapeutic neck dissection for patients with PTC is standard treatment, the role of elective neck dissection is unclear. Despite this, elective paratracheal dissection seems to be gaining momentum despite a lack of evidence to support a survival or locoregional control advantage. Contrary to most other cancers, regional metastases are not a potent adverse predictor for survival in patients with welldifferentiated thyroid carcinoma but do predict for locoregional failure. The incidence of nodal metastases is quite high and is reported to range from 40% to 80%. 1, 5, 6 According to Shaha et al, 5 if every patient with PTC underwent prophylactic neck dissection, the incidence of microscopic metastases would be as high as 70% to 80%. However, the clinical incidence of recurrence usually does not exceed 10% to 20%. Some theories elaborated to explain that discrepancy are that occult metastases fail to grow, may regress with TSH suppression, or more probably are controlled as a result of radioactive iodine ablation. Clearly, there are yet undetermined biological differences between nodal diseases those progresses and that which is never clinically apparent.
Regional Recurrence in PTC
In our cohort, only 6.7% of patients developed regional recurrence. Persistence or recurrence of lymph node metastases have been reported to occur in 5% to 20% of patients with PTC. 3, 7 It could be argued that a longer follow-up period would result in a higher rate of locoregional recurrence. However, McConahey et al 8 showed that the incidence of locoregional recurrence is greatest in the first 3 years after initial treatment. The incidence was 16.3 per 1000 person-years within the first 3 years compared with 2.5 per 1000 person-years subsequently. 8 Bardet et al 3 found a 7% lymph node recurrence rate and almost half of these recurrences occurred in the first year after diagnosis. This has brought some authors to question the cost-benefit of intensive follow-up of low-risk patients beyond the 5-year mark.
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Role of Neck Dissection in PTC
Wada et al, 10 in 2003, examined the clinical significance of prophylactic neck dissection in patients with micropapillary carcinoma. They compared the recurrence rate of 235 patients with micropapillary thyroid carcinoma who underwent prophylactic neck dissection to the recurrence rate of 155 patients with incidental microcarcinoma who did not undergo neck dissection. Despite the high rate of positive lymph node metastases (61% of central neck lymph nodes and 40% of lateral neck lymph nodes), 1 of 235 patients (0.43%) who had a prophylactic neck dissection developed a regional recurrence, compared to only 1 of 155 patients (0.65%) with incidental microcarcinoma and no neck dissection. The size of micropapillary carcinoma influenced the frequency of lymph node metastases, but did not have an effect on nodal recurrence. 10 These observations are in line with the results of our study.
Interestingly, in our cohort, the majority of patients who recurred regionally after a total thyroidectomy without a paratracheal neck dissection developed metastases in ipsilateral level 4, followed closely by levels 3 and 2 (Table 3) . Only 1 patient without a paratracheal neck dissection (0.4%) recurred in the ipsilateral central compartment alone. It is difficult to draw strong conclusions without a suitable control group, but these results do not suggest that our traditional practice of only performing therapeutic dissections should be abandoned in favor of elective ipsilateral paratracheal dissection, especially in the context of routine radioactive iodine ablation. If the ultimate goal is a single operation that achieves athyroglobulinemia or reduces the number of subsequent radioactive iodine treatments, then the high rate of lateral neck disease would support routine bilateral central and lateral neck dissections. However, it seems obvious that the surgical morbidity of adopting such a radical approach would be excessive for an indolent disease.
The ratio of morbidity and benefit is not clear for ipsilateral paratracheal dissection. Some studies have reported rates of permanent hypoparathyroidism as high as 50%. 13 Despite this, evidence is emerging that routine ipsilateral level VI dissection can be performed safely and with low morbidity in expert hands. However, thyroidectomy for PTC is a common operation performed by surgeons of varying clinical and technical expertise and it is unlikely that low complication rates will be maintained if prophylactic central dissection is universally adopted.
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Predictors for Regional Recurrence
Many prognostic factors have been proposed in the literature. Our results support other investigators who have demonstrated that the presence of cervical nodal metastases at the time of diagnosis was a significant prognostic factor for locoregional recurrence. 3, 15, 16 Extension of disease through thyroid capsule and lymphovascular invasion were found to be independent predictors for locoregional failure. Extrathyroidal extension is a well established and potent adverse prognostic factor 17, 18 and is included in most staging systems. Several studies on lymphatic invasion and angioinvasion in PTC have demonstrated that those pathological findings are markers of increased biologic aggressiveness and offer a less favorable longterm prognosis. [19] [20] [21] In fact, the presence of angio/lymphatic invasion would be associated with higher rates of regional and distant metastasis at the time of diagnosis and greater risks of nodal recurrence. 22 It is apparent that more accurate measures of biological activity that can be obtained preoperatively are required to better guide the extent of surgery.
Elective Neck Dissection in the Current Era
The techniques for detecting residual PTC have become increasingly sensitive because of advances in thyroglobulin assays (serum and needle washouts), high-resolution ultrasound and functional imaging techniques. However, this has predominantly enabled the detection of low-volume nodal recurrence of well-differentiated cancers that secrete thyroglobulin and are iodine avid in patients who were never likely to have died of their disease. The current trend toward elective neck dissection is an unsophisticated approach to a complex problem that risks creating more morbidity than the natural course of the disease could ever achieve. The current study suggests that ETE and lymphovascular invasion are independent predictors of regional recurrence. There may be a role for a more selective approach to elective neck dissection in patients with gross ETE identified preor intraoperatively, omitting paratracheal dissection in those without ETE. On the basis of the distribution of recurrence, it may also be reasonable to extend the dissection to include the contralateral central compartment and ipsilateral levels III and IV.
Clinicopathological, sonographic, or molecular parameters that can be determined preoperatively to define which subgroup of patients are likely to benefit from prophylactic neck dissection require further investigation. In 2002, Davies et al 23 discovered an activating mutation in the gene for the B-type Raf kinase (BRAF). The BRAF mutation was found to play an important role in the carcinogenesis and progression of PTC. 24 Kebebew et al 24 determined that the BRAF V600E mutation was associated with more aggressive tumor phenotype and higher rates of recurrent disease in patients with conventional PTC. In their opinion, testing BRAF mutation status could be a useful clinical adjunct in determining or justifying a prophylactic central neck dissection. 24 This seems to be a promising avenue, but it requires further validation.
CONCLUSIONS
The potential benefit of elective central compartment dissection in patients treated with total thyroidectomy and routine radioactive iodine ablation seems to be small in terms of reducing salvage surgery. Further evidence is required to determine the utility and morbidity of this technique in the current setting. Preoperative parameters predicting for regional recurrence would enable selection of patient subgroups most likely to benefit from elective neck dissection.
